Want to see PMHS full AI Analyst Report?
Top Page
Polomar Health Services
(OTC:PMHS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.28
▲(41.00% Upside)
Action:Reiterated
Date:10/11/26
The score is primarily held down by weak financial performance (extreme operating/net losses, negative equity, and negative free cash flow) and a loss-making valuation profile (negative P/E, no dividend yield provided). Technicals are moderately supportive with the price above key moving averages, and the CFO appointment is a modest positive, but neither offsets the current fundamental risk.
Positive Factors
Revenue growth and gross margin
Rapid TTM revenue expansion combined with a solid gross margin indicates that the company is generating meaningful economic value from its offerings. If growth persists and operating costs become better aligned with sales, this gross-profit base could support improved scalability and future earnings potential.
Negative Factors
Extreme operating and net losses
Extremely negative operating and net margins show that the current cost structure is far above the revenue base despite strong gross profitability. This indicates that revenue growth has not yet translated into operating leverage, leaving the company exposed to continued losses until expenses are substantially reduced or sales expand further.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and gross margin
Rapid TTM revenue expansion combined with a solid gross margin indicates that the company is generating meaningful economic value from its offerings. If growth persists and operating costs become better aligned with sales, this gross-profit base could support improved scalability and future earnings potential.
Read all positive factors
Polomar Health Services (PMHS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.17M
Dividend YieldN/A
Average Volume (3M)11.32K
Price to Earnings (P/E)―
Beta (1Y)-0.82
Revenue Growth7688.77%
EPS Growth-359.43%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,380,869
10 Day Avg. Volume21,961
30 Day Avg. Volume11,317
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-18.17
Price to Sales (P/S)34.26
P/FCF Ratio-56.08
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit2.02
Enterprise Value/Ebitda-45.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Polomar Health Services Business Overview & Revenue Model
Company Description
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded...
How the Company Makes Money
null...
Polomar Health Services Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.17M | 648.23K | 58.82K | 0.00 | 34.53K | 0.00 |
| Gross Profit | 1.94M | 460.10K | 30.90K | 0.00 | 34.53K | 0.00 |
| EBITDA | -85.97K | -776.94K | -1.04M | -410.66K | -181.45K | -132.75K |
| Net Income | -9.46M | -10.70M | -1.34M | -416.50K | -181.12K | -168.40K |
Balance Sheet | ||||||
| Total Assets | 814.73K | 390.04K | 9.95M | 244.00 | 261.48K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 178.87K | 132.15K | 6.19K | 244.00 | 225.62K | 0.00 |
| Total Debt | 794.79K | 14.86K | 49.18K | 81.66K | 69.70K | 32.69K |
| Total Liabilities | 1.87M | 1.61M | 14.86K | 13.78K | 74.72K | 35.65K |
| Stockholders Equity | -1.06M | -1.22M | 9.94M | -13.54K | 186.77K | -35.65K |
Cash Flow | ||||||
| Free Cash Flow | -6.96K | -396.00K | -1.11M | -371.86K | -40.93K | -32.69K |
| Operating Cash Flow | -6.96K | -396.00K | -1.02M | -371.86K | -40.93K | -32.69K |
| Investing Cash Flow | 0.00 | 0.00 | -90.89K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 181.15K | 521.95K | 1.11M | 146.49K | 266.55K | 32.69K |
Polomar Health Services Technical Analysis
Positive
0.20
Price Trends
0.19
Positive
0.15
Positive
0.25
Positive
Market Momentum
>-0.01
Negative
67.30
Neutral
61.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMHS, the sentiment is Positive. The current price of 0.2 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.19, and below the 200-day MA of 0.25, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 67.30 is Neutral, neither overbought nor oversold. The STOCH value of 61.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMHS.
Polomar Health Services Risk Analysis
Polomar Health Services disclosed 47 risk factors in its most recent earnings report. Polomar Health Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Polomar Health Services Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $8.17M | -0.54 | -892.31% | ― | 7688.77% | -359.43% | |
44 Neutral | $3.68M | -0.07 | -125.01% | ― | ― | 93.91% | |
43 Neutral | $20.85M | -1.20 | -3.48% | ― | -8.04% | -100.01% | |
42 Neutral | $2.67M | -0.08 | -72.87% | ― | ― | ― | |
38 Underperform | $1.02M | -0.01 | -46.21% | ― | -35.26% | 51.06% |
* Healthcare Sector Average
PMHS
Polomar Health Services
0.29
0.09
44.00%
PRFX
PainReform
0.88
-5.17
-85.49%
UPC
Universe Pharmaceuticals
4.15
-1.85
-30.83%
BJDX
Bluejay Diagnostics
0.82
-10.58
-92.78%
NIVF
NewGenIvf Group
0.07
-977.33
-99.99%
MNDR
Mobile-health Network Solutions Class A
0.85
-20.27
-95.98%
Polomar Health Services Corporate Events
Business Operations and StrategyExecutive/Board Changes
Polomar Health Services Appoints Douglas Beck as CFO
Positive
Jul 20, 2026
On July 15, 2026, Polomar Health Services, Inc. appointed Douglas Beck as Chief Financial Officer and Treasurer, with Beck also assuming the roles of principal financial officer and principal accounting officer as of that date. The appointment ref...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.